Baiyang Investment Group, Inc. (002696.SZ) announced a forecasted net loss of 8-15 million yuan for the year 2024.
Baixiang Group (002696.SZ) issued a performance forecast for the year 2024, expecting a full year net loss of 8 million for the parent company.
Baiyang Investment Group, Inc. (002696.SZ) has released its performance forecast for the year 2024, expecting a net loss attributable to shareholders of 8-15 million RMB, and a non-recurring net loss of 18-25 million RMB.
In the first half of the year, the company's overall operations did not meet expectations due to factors such as the rise in domestic raw material fish prices and shipping costs, a decrease in fish meal prices, and a decline in the company's aquaculture feed sales. In the second half of 2024, the company adjusted its management team, optimized its strategic direction and operating strategies in a timely manner, and saw significant improvement in its operating performance. In terms of exports of aquatic food products, the overseas demand for tilapia steadily increased, and with the decline in raw material fish prices and the appreciation of the US dollar in the second half of the year, the company's tilapia product exports increased in volume and value, and its market share improved. Feed sales also showed a steady recovery in the second half of the year, stabilizing the company's operating performance. Additionally, in accordance with the Enterprise Accounting Standards and company accounting policies, the company plans to set aside impairment provisions for some assets that may be impaired during the reporting period.
Related Articles

Yahong Pharmaceutical (688176.SH): APL-2401 clinical trial application approved by the National Medical Products Administration.

Yabao Pharmaceutical Group (600351.SH): GLX002 has obtained the notice of approval for clinical trial of the drug.

New Stock News | Hua Rong Bio-B (02396) IPO ends, with a subscription amount of HK$53.6 billion, oversubscribed 594 times.
Yahong Pharmaceutical (688176.SH): APL-2401 clinical trial application approved by the National Medical Products Administration.

Yabao Pharmaceutical Group (600351.SH): GLX002 has obtained the notice of approval for clinical trial of the drug.

New Stock News | Hua Rong Bio-B (02396) IPO ends, with a subscription amount of HK$53.6 billion, oversubscribed 594 times.

RECOMMEND

Super Central Bank Week Arrives! Japan Leads With A Rate Hike As Developed Economies End The Rate‑Cut Cycle, Will The Fed Cut Alone Next Year?
16/12/2025

What Guidance Does The Economic Work Conference Offer For Cross‑Year Market Direction?
16/12/2025

Trade Surplus Tops One Trillion USD: New Challenges For China’s Foreign Trade | Instant Commentary
16/12/2025


